

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF CLASS 1.1 INNOVATIVE TRADITIONAL CHINESE
MEDICINE XINGPI JIEYU TABLETS FOR MARKETING

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors of the latest business development of the Group.

Reference is made to the Company’s voluntary announcement dated 25 June 2025 (the “**Announcement**”) in relation to the acceptance by the NMPA of the new drug application of Yushuda Tablets, the Class 1.1 innovative traditional Chinese medicine, submitted by Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. (“**Tongjitang Pharmaceutical**”), a subsidiary of the Group. Unless otherwise defined, terms used herein have the same meanings as those defined in the Announcement.

The Board is pleased to announce that, following the completion of technical evaluation, on-site inspection, sampling and testing by the NMPA, the Class 1.1 innovative traditional Chinese medicine Xingpi Jieyu Tablets (which is the standardized generic name approved by the NMPA for the pharmaceutical product, formerly referred to as “Yushuda Tablets” in the Announcement) has been approved for marketing. The marketing authorization holder is Tongjitang Pharmaceutical.

ABOUT XINGPI JIEYU TABLETS

Xingpi Jieyu Tablets (the “**Drug**”) demonstrates effects of invigorating the spleen, resolving dampness, and regulating qi to alleviate stagnation. It is indicated for mild-to-moderate depression, with symptoms including depressed mood, low spirits, apathetic expression, fatigue, insomnia and

excessive dreaming, shortness of breath and reluctance to speak, poor appetite, heavy head and limb sluggishness, sticky sensation in the mouth, dull complexion, pale tongue with white greasy or gray greasy coating, and slippery or wiry pulse.

As disclosed in the Announcement, Tongjitang Pharmaceutical completed a Phase III clinical trial of the Drug for treating mild-to-moderate depression in 2024. Results demonstrated that the Drug offered favorable safety and efficacy profiles in subjects with mild-to-moderate depression presenting as “damp-turbidity distressing the spleen with qi stagnation syndrome”, and the effect was significantly superior to that of the placebo group.

The marketing of the Drug provides a new treatment option for patients with mild-to-moderate depression.

IMPACT ON THE COMPANY AND RISK REMINDER

The approval of the Drug for marketing further enriches the Group’s portfolio of Chinese patent medicines and is expected to have a positive impact on the Group’s future operating performance. However, the extent of the impact will depend on its future production, sales and marketing promotion. The actual sales performance of the Drug after marketing may be subject to various factors such as medical insurance policies, tender procurement, market competition and the progress of academic promotion, and is subject to uncertainty.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
GUO Jinhong
Chairman

Hong Kong, 4 September 2026

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. GUO Jinhong, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui, Mr. CHEN Kun and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.